How should I manage a patient with medullary calcinosis and hypertension who has normal kidney function?

Management of Medullary Calcinosis with Hypertension and Normal Kidney Function

Treat the hypertension with thiazide diuretics as first-line therapy, which uniquely addresses both the hypertension and reduces urinary calcium excretion to prevent progression of nephrocalcinosis. 1

Diagnostic Workup

Before initiating treatment, obtain the following to identify the underlying cause and guide management:

• 24-hour urine collection for calcium, creatinine, citrate, and sodium excretion 2
• Serum electrolytes including calcium, phosphate, potassium, and bicarbonate to identify metabolic abnormalities
• Parathyroid hormone (PTH) and vitamin D levels to exclude hypoparathyroidism or vitamin D disorders 2
• Plasma renin and aldosterone if hypokalemia is present, as medullary sponge kidney can activate the renin-angiotensin-aldosterone system 3
• Renal imaging (ultrasound or CT) to assess extent of nephrocalcinosis and exclude nephrolithiasis 2

Hypertension Management

Primary therapy: Thiazide diuretics are the optimal choice because they:

• Lower blood pressure effectively
• Reduce urinary calcium excretion (hypocalciuric effect), directly addressing the pathophysiology of nephrocalcinosis 1
• Prevent progression of calcium stone formation 1

Specific dosing:

• Hydrochlorothiazide 25 mg twice daily or 50 mg once daily
• Chlorthalidone 25 mg once daily
• Indapamide 2.5 mg once daily 1

Critical adjunctive measures:

• Sodium restriction (<2,300 mg/day) to maximize the hypocalciuric effect and limit potassium wasting 1
• Potassium citrate supplementation (typically required with thiazide therapy) to prevent hypokalemia and provide additional stone prevention through urinary alkalinization 1
• Adequate hydration to maintain dilute urine and reduce crystallization risk 4

If Thiazides Are Insufficient

Add ACE inhibitors or ARBs as second-line agents, particularly if:

• Blood pressure remains >130/80 mmHg despite thiazide therapy 5, 6
• There is evidence of proteinuria or early kidney dysfunction 7, 5
• The patient has secondary hyperaldosteronism (as seen in some MSK cases) 3

Target blood pressure: <130/80 mmHg based on current guidelines for patients with kidney disease risk 5, 6

Monitoring Strategy

Every 3-6 months initially:

• Serum electrolytes (potassium, calcium, bicarbonate)
• Kidney function (creatinine, eGFR)
• 24-hour urinary calcium excretion to ensure hypocalciuric response 2

Every 5 years if asymptomatic, or sooner if symptoms develop:

• Renal imaging to assess progression of nephrocalcinosis 2

Annually:

• Blood pressure control assessment
• Urinary calcium monitoring 2

Critical Pitfalls to Avoid

1. Do not use calcium channel blockers as first-line therapy in this setting—they lack the beneficial hypocalciuric effect of thiazides
2. Avoid high-dose vitamin D supplementation without careful monitoring, as it can worsen hypercalciuria and nephrocalcinosis 2
3. Monitor for hypokalemia when using thiazides; potassium citrate is preferred over potassium chloride as it provides dual benefit (potassium replacement + stone prevention) 1
4. Do not combine ACE inhibitors and ARBs unless there is proteinuric kidney disease, as this increases risk of hyperkalemia and acute kidney injury 8, 7

Special Considerations

If distal renal tubular acidosis is identified (common with medullary sponge kidney), potassium citrate becomes even more critical to correct acidosis and prevent stone formation 9. If secondary hyperaldosteronism is documented, consider adding spironolactone (50-100 mg daily) as it addresses both hypertension and the underlying hormonal abnormality 10, 3.